[
sinopharm
]
China: Over 4 million Covid-19 vaccine doses administered in emergency use
Reuters
PUBLISHED ON JAN 09, 2021 10:29 AM IST
Two vaccines respectively from two institutes owned by CNBG, a unit of state-backed China National Pharmaceutical Group (Sinopharm), are included in China's emergency vaccination scheme.

Covid-19 vaccine update: Pan-India dry run on Saturday, WHO approves Pfizer’s candidate
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON JAN 01, 2021 10:58 AM IST
The European Union (EU) will review a request by Pfizer’s German partner, BioNTech SE, for an additional vaccine dose from each vial, instead of the five currently approved.

Pakistan to buy 1.1 million doses of Sinopharm’s Covid-19 vaccine
By Press Trust of India | Edited by Shankhyaneel Sarkar | Islamabad
PUBLISHED ON DEC 31, 2020 05:03 PM IST
China on Thursday granted conditional approval to the country’s first homegrown COVID-19 vaccine developed by Sinopharm.

Sinopharm’s Covid-19 vaccine 79% effective, seeks approval in China
By Reuters| Posted by: Harshit Sabarwal | Beijing
PUBLISHED ON DEC 30, 2020 01:34 PM IST
The efficacy rate, based on interim analysis of Phase 3 clinical trials, is lower than 86% rate for the same vaccine announced by the United Arab Emirates on Dec. 9, based on preliminary data from trials there.

China puts the pedal to the metal on vaccine diplomacy. There are concerns | Analysis
By Shishir Gupta | Hindustan Times, New Delhi
UPDATED ON DEC 17, 2020 07:31 PM IST
China has been shipping consignments of its Covid vaccines despite the absence of Phase III safety and efficacy data.

Covid-19: UAE launches inoculation using Chinese drugs giant Sinopharm’s vaccine
By Agence France-Presse | Posted by Prashasti Singh | Abu Dhabi
UPDATED ON DEC 15, 2020 07:01 AM IST
Gulf countries UAE and Bahrain, where third-phase trials of the Sinopharm vaccine were carried out, have both officially registered it for public use after it was previously approved for emergency use for frontline health workers.

Top Chinese vaccine maker seeks govt nod to market Covid-19 shots
By Sutirtho Patranobis , edited by Vinod Janardhanan | Hindustan Times, Beijing
UPDATED ON NOV 25, 2020 06:37 PM IST
The company, which is carrying out clinical trials of the candidate vaccine abroad said it had collected data from host countries such as UAE.

Chinese vaccine maker seeks approval for public use of Covid-19 shot
By Bloomberg | Posted by Srivatsan K C
UPDATED ON NOV 25, 2020 10:34 AM IST
With the application, CNBG will likely become the first developer outside of Russia to see its shots made available for general public use, underscoring China’s determination to be a major player in supplying inoculations to countries around the world.

Chinese experimental Covid-19 vaccine given to 1 million people
By Sutirtho Patranobis | Hindustan Times, Beijing
UPDATED ON NOV 20, 2020 12:09 AM IST
China launched the emergency vaccine use programme in July, mainly directed towards essential workers and those going abroad

As Covid-19 cases cross 24 million globally, a look at 5 much-awaited vaccines
By hindustantimes.com | Edited by Prashasti Singh | Hindustan Times, New Delhi
UPDATED ON AUG 27, 2020 02:34 PM IST
United States has the highest number of cases in the world (5.9 million), followed by Brazil (3.72 million) and India (3.31 million).

Oxford Covid-19 vaccine could be the first to be available to Indians: 5 key developments
By hindustantimes.com | Edited by Sparshita Saxena | Hindustan Times, New Delhi
UPDATED ON AUG 19, 2020 10:52 AM IST
State-owned Chinese pharmaceutical company SinoPharm said its Covid-19 vaccine will be commercially available by the end of the year.

China Sinopharm chief rules out high price for coronavirus vaccine
By Reuters| Posted by Susmita Pakrasi | Beijing
PUBLISHED ON AUG 18, 2020 10:33 AM IST
Sinopharm has said its experimental vaccine could be ready for public use by the end of this year. It has entered a late-stage human test in the United Arab Emirates to gather proof of efficacy for final regulatory approvals.